(VIANEWS) – Evercore Partners (EVR), Safe Bulkers (SB), Steven Madden, Ltd. (SHOO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Evercore Partners (EVR)
30.8% sales growth and 17.78% return on equity
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Evercore Partners has a trailing twelve months EPS of $6.39.
PE Ratio
Evercore Partners has a trailing twelve months price to earnings ratio of 30.87. Meaning, the purchaser of the share is investing $30.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.78%.
Volume
Today’s last reported volume for Evercore Partners is 303366 which is 4.7% below its average volume of 318334.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 72.9% and 86.2%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.5%, now sitting on 2.43B for the twelve trailing months.
2. Safe Bulkers (SB)
12.9% sales growth and 10.69% return on equity
Safe Bulkers, Inc., together with its subsidiaries, provides marine drybulk transportation services. It owns and operates drybulk vessels for transporting bulk cargoes primarily coal, grain, and iron ore. The company has a fleet of 47 drybulk vessels having an aggregate carrying capacity of 4,719,600 deadweight tons. Its fleet consists of 10 Panamax class vessels, 11 Kamsarmax class vessels, 18 post-Panamax class vessels, and 8 Capesize class vessels. Safe Bulkers, Inc. was incorporated in 2007 and is based in Monaco.
Earnings Per Share
As for profitability, Safe Bulkers has a trailing twelve months EPS of $0.67.
PE Ratio
Safe Bulkers has a trailing twelve months price to earnings ratio of 8.48. Meaning, the purchaser of the share is investing $8.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.69%.
3. Steven Madden, Ltd. (SHOO)
10.7% sales growth and 21.62% return on equity
Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward branded and private label footwear, accessories, and apparel for women, men, and children in the United States and internationally. Its Wholesale Footwear segment provides footwear under the Steve Madden, Steven by Steve Madden, Madden Girl, BB Dakota, Dolce Vita, DV Dolce Vita, Betsey Johnson, GREATS, Blondo, Anne Klein, Mad Love, Superga, Madden NYC, and COOL Planet brands, as well as private label footwear. The company's Wholesale Accessories/Apparel segment offers handbags, apparel, small leather goods, belts, soft accessories, fashion scarves, wraps, gifting, and other accessories under the Steve Madden, BB Dakota, Anne Klein, Betsey Johnson, Cejon, Madden NYC, and Dolce Vita brands, as well as private label handbag and accessories to department stores, mass merchants, off-price retailers, online retailers, specialty stores, and independent stores. Its Direct-to-Consumer segment operates Steve Madden and Superga full-price retail stores, Steve Madden outlet stores, and Steve Madden shop-in-shops, as well as digital e-commerce websites, including SteveMadden.com, DolceVita.com, betseyjohnson.com, Blondo.com, GREATS.com, and Superga-USA.com. The company's Licensing segment licenses its Steve Madden, Madden Girl, and Betsey Johnson trademarks. Its First Cost segment operates as a buying agent for footwear products under private labels for national chains, specialty retailers, and value-priced retailers. As of December 31, 2021, it owned and operated 214 brick-and-mortar retail stores that included 147 Steve Madden full-price stores, 66 Steve Madden outlet stores, and 1 Superga store, as well as 6 e-commerce websites. Steven Madden, Ltd. was incorporated in 1990 and is headquartered in Long Island City, New York.
Earnings Per Share
As for profitability, Steven Madden, Ltd. has a trailing twelve months EPS of $2.42.
PE Ratio
Steven Madden, Ltd. has a trailing twelve months price to earnings ratio of 18.32. Meaning, the purchaser of the share is investing $18.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.62%.
Volume
Today’s last reported volume for Steven Madden, Ltd. is 361111 which is 52.89% below its average volume of 766673.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 10.6% and 5.7%, respectively.
Sales Growth
Steven Madden, Ltd.’s sales growth is 12.6% for the current quarter and 10.7% for the next.
4. Armstrong World Industries (AWI)
9.7% sales growth and 40.35% return on equity
Armstrong World Industries, Inc., together with its subsidiaries, designs, manufactures, and sells ceiling systems primarily for use in the construction and renovation of residential and commercial buildings in the United States, Canada, and Latin America. The company operates through Mineral Fiber and Architectural Specialties segments. The company produces suspended mineral fiber, soft fiber, fiberglass wool, and metal ceiling systems, as well as wood, wood fiber, glass-reinforced-gypsum, and felt ceiling and wall systems; ceiling component products, such as ceiling perimeters and trims, as well as grid products that support drywall ceiling systems; ceilings and walls for use in commercial settings; and acoustical controls and architectural cast ceilings, walls, facades, columns, and moldings solutions. It sells its commercial ceiling and architectural specialties products to resale distributors and ceiling system contractors; and residential ceiling products to wholesalers and retailers, such as large home centers. The company was incorporated in 1891 and is headquartered in Lancaster, Pennsylvania.
Earnings Per Share
As for profitability, Armstrong World Industries has a trailing twelve months EPS of $5.31.
PE Ratio
Armstrong World Industries has a trailing twelve months price to earnings ratio of 21.66. Meaning, the purchaser of the share is investing $21.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.35%.
Yearly Top and Bottom Value
Armstrong World Industries’s stock is valued at $115.02 at 20:22 EST, below its 52-week high of $125.56 and way higher than its 52-week low of $68.35.
Volume
Today’s last reported volume for Armstrong World Industries is 224833 which is 30.73% below its average volume of 324604.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 12.3% and 6.2%, respectively.
5. Vertex Pharmaceuticals (VRTX)
8.2% sales growth and 24.38% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.89.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.55. Meaning, the purchaser of the share is investing $28.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.38%.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 1164750 which is 7.99% below its average volume of 1265930.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 10.18B for the twelve trailing months.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 6.7% for the current quarter and 8.2% for the next.
6. Stag Industrial (STAG)
7.3% sales growth and 5.37% return on equity
We are a REIT focused on the acquisition, ownership, and operation of industrial properties throughout the United States. Our platform is designed to (i) identify properties for acquisition that offer relative value across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants through the principled application of our proprietary risk assessment model, (ii) provide growth through sophisticated industrial operation and an attractive opportunity set, and (iii) capitalize our business appropriately given the characteristics of our assets. We are organized and conduct our operations to maintain our qualification as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”), and generally are not subject to federal income tax to the extent we currently distribute our income to our stockholders and maintain our qualification as a REIT. We remain subject to state and local taxes on our income and property and to U.S. federal income and excise taxes on our undistributed income. As of December 31, 2023, we owned 569 buildings in 41 states with approximately 112.3 million rentable square feet, consisting of 493 warehouse/distribution buildings, 70 light manufacturing buildings, one flex/office building, and five Value Add Portfolio buildings. In addition, as of December 31, 2023, we had six development projects (which are not included in the building count noted above). While the majority of our portfolio consists of single-tenant properties, we also own a growing number of multi-tenant properties. As of December 31, 2023, our buildings were approximately 98.2% leased, with no single tenant accounting for more than approximately 2.9% of our total annualized base rental revenue and no single industry accounting for more than approximately 11.0% of our total annualized base rental revenue. We intend to maintain a diversified mix of tenants to limit our exposure to any single tenant or industry. As of December 31, 2023, our Operating Portfolio was approximately 98.4% leased. SL Rent Change on new and renewal leases together grew approximately 44.0% and 24.3% during the years ended December 31, 2023 and 2022, respectively, and our Cash Rent Change on new and renewal leases together grew approximately 31.0% and 14.3% during the years ended December 31, 2023 and 2022, respectively. We have fully integrated acquisition, leasing and operations platforms led by a senior management team with decades of industrial real estate experience. Our mission is to deliver attractive long-term stockholder returns in all market environments by growing cash flow through disciplined investment in high-quality real estate while maintaining a strong balance sheet.
Earnings Per Share
As for profitability, Stag Industrial has a trailing twelve months EPS of $0.99.
PE Ratio
Stag Industrial has a trailing twelve months price to earnings ratio of 35.9. Meaning, the purchaser of the share is investing $35.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 721.83M for the twelve trailing months.
Yearly Top and Bottom Value
Stag Industrial’s stock is valued at $35.54 at 20:22 EST, way under its 52-week high of $39.61 and way above its 52-week low of $31.69.
